All In Biotech

Investigational drug · Phase 3

MK-1045

Also called: CN-201

Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

6

6 still active

All registered trials

8

Any phase or sponsor naming "MK-1045"

First trial start

2022

Nov 1, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "MK-1045", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Non-Hodgkin
  • Lymphoma, Follicular
  • Acute Lymphoblastic Leukemia
  • Follicular Lymphoma
  • Chronic Lymphocytic Leukaemia
  • Small Lymphocytic Lymphoma
  • Hematologic Malignancies
  • B-cell Acute Lymphoblastic Leukemia
  • Diffuse Large B-Cell Lymphoma

Approved drugs for the same conditions: Acute lymphoblastic leukemia · Lymphoma (non-Hodgkin) · Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "MK-1045" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Lymphoma, Large B-Cell, Diffuse

  • MK-2140Zilovertamab Vedotin, VLS-101Phase 39 trials

    Merck & Co. · Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia

  • JNJ-90014496Phase 21 trial

    Johnson & Johnson (Janssen) · Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

  • Relmacabtagene AutoleucelJWCAR029Phase 21 trial

    Shanghai Ming Ju Biotechnology Co., Ltd. · Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.